<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01972490</url>
  </required_header>
  <id_info>
    <org_study_id>ACCMCLM</org_study_id>
    <nct_id>NCT01972490</nct_id>
  </id_info>
  <brief_title>Avastin in Combination With Chemotherapy for RAS Mutant Unresectable Colorectal Liver-limited Metastases</brief_title>
  <official_title>Study of Avastin in Combination With Chemotherapy for the First Line Treatment of RAS Mutant Unresectable Colorectal Liver-limited Metastases</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xu jianmin</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fudan University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study, the investigators assessed the effect of avastin in combination with&#xD;
      chemotherapy in the treatment of RAS mutant-type, unresectable colorectal liver-limited&#xD;
      metastases&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients will be eligible for inclusion if the patients have histologically confirmed&#xD;
      colorectal adenocarcinoma with RAS mutant liver-confined metastases deemed non-resectable.&#xD;
      Eligible patients will be randomly assigned to chemotherapy plus avastin (arm A) or&#xD;
      chemotherapy alone (arm B). Treatment will continue until tumor response indicates&#xD;
      suitability for surgery for liver metastases or until disease progression or unacceptable&#xD;
      toxic effects. The primary endpoint is the conversion rate to radical resection for liver&#xD;
      metastases，which will be assessed by local multidisciplinary team (includes more than three&#xD;
      liver surgeons and one radiologist) with the use of contrast-enhanced CT or MRI after 4&#xD;
      cycles and then every other 4 cycles up to 12 cycles. To provide an objective assessment of&#xD;
      changes in resectability, radiological images will be presented by a radiologist to more than&#xD;
      3 liver surgeons, who are blinded to the clinical data. Patients will be considered&#xD;
      resectable if 50% or more of surgeons vote for radical resection of LM. For patients whose&#xD;
      liver-metastases are assessed resectable, resection should be scheduled to be performed&#xD;
      within 2~3 weeks of the last treatment cycle. Following resection, patients will be advised&#xD;
      to continue the same therapeutic regimen until the treatments reach a sum of 12 cycles.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 2013</start_date>
  <completion_date type="Actual">June 2019</completion_date>
  <primary_completion_date type="Actual">December 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>the rate of patients converted to resection for liver metastases</measure>
    <time_frame>3 years</time_frame>
    <description>To explore whether avastin in combination with chemotherapy as treatment could improve the resection rate in patients with RAS mutant-type, unresectable colorectal liver-limited metastases compared with chemotherapy alone.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>progression free survival</measure>
    <time_frame>3 years</time_frame>
    <description>PFS will be defined as the period from the first day of avastin treatment or chemotherapy to the date of disease progression (PD) or to death. Patients without PD who discontinued the study for any reason is censored at the last on-study tumor assessment date.or distant(i.e. metastasis) disease recurrence or death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>3 years</time_frame>
    <description>OS will be calculated from randomization to death from any cause or the date of the last follow-up, at which point the data will be censored.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>tumor response</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">241</enrollment>
  <condition>Colorectal Neoplasms</condition>
  <arm_group>
    <arm_group_label>ARM A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients received avastin in combination with mFOLFOX6</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ARM B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients received mFOLFOX6 alone</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>avastin</intervention_name>
    <description>Drug: avastin On day 1 of a 14 day treatment cycle, patients received a 2-hour infusion of avastin (5mg/kg) followed by chemotherapy of mFOLFOX6 until progressive disease or unacceptable toxicity.</description>
    <arm_group_label>ARM A</arm_group_label>
    <other_name>Bevacizumab</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mFOLFOX6</intervention_name>
    <description>mFOLFOX-6 (oxaliplatin, 85mg/m2 on day 1 infused during 2 hours;LV400mg/m2 on days 1 infused during 2 hours, followed by FU 400 mg/m2 intravenous bolus then 2400 mg/m2 continuous infusion for 46 hours)</description>
    <arm_group_label>ARM A</arm_group_label>
    <arm_group_label>ARM B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age ≥ 18 and ≤ 75 years;&#xD;
&#xD;
          2. Primary tumour was histologically confirmed colorectal adenocarcinoma;&#xD;
&#xD;
          3. Together with clinical or radiological evidence of first occurrence of non-resectable&#xD;
             liver-only metastases&#xD;
&#xD;
          4. With evidence of tumor RAS gene mutant status;&#xD;
&#xD;
          5. With at least one measurable tumor.&#xD;
&#xD;
          6. Performance status (ECOG) 0~1&#xD;
&#xD;
          7. A life expectancy of ≥ 3 months&#xD;
&#xD;
          8. Adequate hematological function: Neutrophils≥1.5 x109/l and platelet count≥100 x109/l;&#xD;
             Hb ≥9g/dl (within 1 week prior to randomization)&#xD;
&#xD;
          9. Adequate hepatic and renal function: Serum bilirubin≤1.5 x upper limit of normal&#xD;
             (ULN), alkaline phosphatase ≤5x ULN, and serum transaminase (either AST or ALT) ≤ 5 x&#xD;
             ULN(within 1 week prior to randomization);&#xD;
&#xD;
         10. Written informed consent for participation in the trial.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Previous exposure to target therapy, chemotherapy, radiotherapy or intervention&#xD;
             therapy for colorectal liver metastases.&#xD;
&#xD;
          2. Known or suspected extrahepatic metastases.&#xD;
&#xD;
          3. Patients with known hypersensitivity reactions to any of the components of the study&#xD;
             treatments.&#xD;
&#xD;
          4. Having previously participated in a study which included a possibility of being&#xD;
             allocated to avastin therapy (whether or not the patient actually received avastin)&#xD;
&#xD;
          5. Clinically relevant coronary artery disease or a history of a myocardial infarction&#xD;
             within the last 12 months or left ventricular ejection fraction (LVEF) below the&#xD;
             institutional range of normal&#xD;
&#xD;
          6. Acute or sub-acute intestinal occlusion&#xD;
&#xD;
          7. Pregnancy (absence confirmed by serum/urine β-HCG) or breast-feeding&#xD;
&#xD;
          8. Other previous malignancy within 5 years, with exception of a history of a previous&#xD;
             basal cell carcinoma of the skin or pre-invasive carcinoma of the cervix&#xD;
&#xD;
          9. Known drug abuse/ alcohol abuse&#xD;
&#xD;
         10. Legal incapacity or limited legal capacity&#xD;
&#xD;
         11. Pre-existing peripheral neuropathy.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Zhongshan Hospital, Fudan University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>September 23, 2013</study_first_submitted>
  <study_first_submitted_qc>October 29, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 30, 2013</study_first_posted>
  <last_update_submitted>December 15, 2019</last_update_submitted>
  <last_update_submitted_qc>December 15, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 17, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Fudan University</investigator_affiliation>
    <investigator_full_name>Xu jianmin</investigator_full_name>
    <investigator_title>Jianmin Xu, PhD Fudan University</investigator_title>
  </responsible_party>
  <keyword>colorectal neoplasms</keyword>
  <keyword>liver metastasis</keyword>
  <keyword>chemotherapy</keyword>
  <keyword>avastin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

